← Leaderboards
Todd B Reynolds
Whitehead Institute For Biomedical Res
$5,793,633
Attributed
$5,793,633
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $847.7K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,793,633 · 6
By mechanism
R01$3,700,950 · 2
T32$1,427,713 · 1
R21$409,337 · 1
R03$136,829 · 1
F32$118,804 · 1
Top collaborators
No co-investigators on record.
Most similar at Whitehead Institute For Biomedical Res
Same institution · by research overlap
- Julia R Koehler$7,967,257
- Benjamin K Chen$29,019,452
- Gerald R Fink$18,432,935
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMycosesCandidaFungusCandida AlbicansVirulenceLifeAntifungal AgentsProteinsSaccharomyces CerevisiaeMutantInfectionSignal TransductionBiologyMammalsPathway InteractionsCellsGenesCell WallCellular BiologySystemic InfectionIn VitroExhibitsAlleles
Grant awards (20)
Integrated Membrane Program (IMP)$321,270
T32 · FY2025 · GM · contact PI
Regulation of Ã(1,3)-glucan exposure in Candida albicans$518,119
R01 · FY2024 · AI · contact PI
Integrated Membrane Program (IMP)$329,616
T32 · FY2024 · GM · contact PI
Regulation of Ã(1,3)-glucan exposure in Candida albicans$508,939
R01 · FY2023 · AI · contact PI
Integrated Membrane Program (IMP)$318,321
T32 · FY2023 · GM · contact PI
Regulation of Ã(1,3)-glucan exposure in Candida albicans$497,866
R01 · FY2022 · AI · contact PI
Integrated Membrane Program (IMP)$312,217
T32 · FY2022 · GM · contact PI
Regulation of Ã(1,3)-glucan exposure in Candida albicans$495,114
R01 · FY2021 · AI · contact PI
Integrated Membrane Program (IMP)$146,289
T32 · FY2021 · GM · contact PI
Regulation of Ã(1,3)-glucan exposure in Candida albicans$513,689
R01 · FY2020 · AI · contact PI
Identification of CDP-DAG and serine binding sites in Candida albicans phosphatidylserine synthase, an antifungal drug target$223,457
R21 · FY2018 · AI · contact PI
Identification of CDP-DAG and serine binding sites in Candida albicans phosphatidylserine synthase, an antifungal drug target$185,880
R21 · FY2017 · AI · contact PI
Screen for phosphatidylserine synthase inhibitors: antifungals & lipid probes$393,411
R01 · FY2015 · AI · contact PI
Screen for phosphatidylserine synthase inhibitors: antifungals & lipid probes$393,091
R01 · FY2014 · AI · contact PI
Screen for phosphatidylserine synthase inhibitors: antifungals & lipid probes$380,721
R01 · FY2013 · AI · contact PI
Role of the OPI1 gene in controlling viability of Candida glabrata$67,607
R03 · FY2008 · AI · contact PI
Role of the OPI1 gene in controlling viability of Candida glabrata$69,222
R03 · FY2007 · AI · contact PI
CONTROL OF GENOME SIZE$46,192
F32 · FY2002 · GM
CONTROL OF GENOME SIZE$40,196
F32 · FY2001 · GM
CONTROL OF GENOME SIZE$32,416
F32 · FY2000 · GM